pharmaphorum

SEPTEMBER 26, 2022

It is usually treated with chemotherapy, but has a high rate of relapse and a low five-year survival rate of between 12% and 14%. ATL is a rare and highly aggressive form of non-Hodgkin lymphoma (NHL), generally associated with infection by the HTLV-1 retrovirus, that can manifest as either a lymphoma or a leukaemia.

Chemotherapy 96

Chemotherapy Labelling FDA 96

pharmaphorum

JANUARY 18, 2021

Johnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain (AL) amyloidosis, a rare and often fatal blood cell disorder. Until now people with AL amyloidosis have had to rely on chemotherapy, with its accompanying side effects, and other drugs to tackle organ failure once damage gets severe.

Chemotherapy 98

Chemotherapy FDA 98

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. They are not US Food and Drug Administration (FDA)-approved for these patients due to the lack of benefit. 2012; 23(8): 6 – 9. Personalized medicine at FDA.

Immunization 92

Immunization Chemotherapy FDA 92

pharmaphorum

APRIL 20, 2021

Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the combination of Erleada (apalutamide) and Zytiga (abiraterone) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Chemotherapy 52

Chemotherapy FDA 52

pharmaphorum

SEPTEMBER 29, 2020

China’s Junshi Biosciences has said it plans filings for a new cancer immunotherapy after its toripalimab outperformed standard chemotherapy in cancer of the upper throat in a phase 3 trial. It has also been granted orphan drug designation by the FDA for mucosal melanoma.

Chemotherapy 40

Chemotherapy FDA 40

PharmaShots

MARCH 29, 2023

Lupin has earned the US FDA approval for the generic version of Banzel as Rufinamide Oral Suspension. It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. The exact mechanism of action is uncertain. Glenmark has also released its generic drug version in the US market.

FDA 49

FDA Chemotherapy Immunization Dosage 49

European Pharmaceutical Review

JULY 4, 2023

Since the first ADC was approved by the EMA in 2012, they have generated a great deal of interest in the oncology field because of their potential to address many of the challenges of traditional chemotherapy options.

Communication 82

Communication Dosage Chemotherapy Documentation 82